Breaks Categories: News

MondayOct 04, 2021 9:48 am

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Study Results Confirming Correlation Between CDA Score, Risk of Cancer

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, has reached a significant milestone and positive result in its general-population, cancer-risk assessment tests and subsequent follow-up study. At the end of September 2021, healthcare providers confirmed more than 2,000 cancer, precancer and disease cases. According to the announcements, those cases include 22 identified types of cancer, 25 identified types of precancer and multiple other related diseases. The company also noted that based on an initial analysis, the confirmed cases strongly correlate to CDA test scores. These…

Continue Reading

FridayOct 01, 2021 11:32 am

BioMedNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) to Host Live Event Highlighting New Potential Treatments for Alcohol Use Disorder, Binge Drinking

Clearmind Medicine (CSE: CMND), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announced that it will host Psychedelics for Alcoholism. The live virtual event highlights new potential treatments for alcohol use disorder and binge drinking. Registration is open and free to all for the online event, which is slated to start at 12 p.m. ET/9 a.m. PT on Oct. 20, 2021. The event will feature brief speaker presentations followed by a discussion with a question-and-answer session. The company has curated a panel of scientists, thought…

Continue Reading

FridayOct 01, 2021 10:24 am

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) First Half Revenue Numbers Up by 128.5%, Non-GAAP Loss Down by 18.3%

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has released it unaudited financial results for the six months ended June 30, 2021. Highlights of the report include total revenues reaching an estimated  $1.4 million, an increase of 128.5% compared to the same period in 2020; gross profit margin of 61.4%, an increase of 16.1 percentage points from the same six-month period in 2020; and the average selling price of CDA-based tests being  $71, also an increase over last year’s average price for the same period. The company also reported a decrease in non-GAAP…

Continue Reading

ThursdaySep 30, 2021 10:23 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Doses First Group of Patients in Potentially Pivotal Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced the dosing of the first patients in its Berubicin clinical development program for the treatment of recurrent glioblastoma multiforme (“GBM”), one of the most aggressive types of brain cancer. According to the update, further patient enrollment, randomization and dosing is currently underway as well as a robust lineup of globally located clinical sites, which are advancing toward activation and enrollment. “As one of the most aggressive, deadly and treatment-resistant cancers that…

Continue Reading

WednesdaySep 29, 2021 10:43 am

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Announces Beta Launch of MiBoKo

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the beta launch of MiBoKo, a new metabolic health program utilizing a noninvasive glucose sensor along with an AI mobile application. According to the update, Nemaura’s Chief Executive Officer Dr. Faz Chowdhury will discuss MiBoKo in more detail during his corporate presentation scheduled for today, Sept. 29, 2021, at 11:10 a.m. ET during the Benzinga Healthcare Small Cap Conference. Investors can access the presentation by registering for the conference at https://ibn.fm/tbmt0. “A person’s response to…

Continue Reading

TuesdaySep 28, 2021 1:23 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Initiates Pilot Program with Four 20 Pharma in Germany

RYAH Group (CSE: RYAH) today announced that it has completed an initial shipment of its proprietary RYAH Smart Dry Herb Inhalers for use in a pilot study to be conducted by Four 20 Pharma GmbH, a leading manufacturer, wholesaler and importer of medical cannabis and medical devices. The study is being conducted in preparation for a wider distribution strategy for the RYAH Smart Dry Herb Inhaler and data analytics platform in the German market. Four 20 is expected to sponsor the launch of an observational study using the RYAH inhalers in order to collect accurate patient feedback on consumption of…

Continue Reading

TuesdaySep 28, 2021 11:25 am

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) to Present at Benzinga Healthcare Small Cap Conference

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research in psychedelics, today announced that its CEO and President Kelsey Ramsden will present and participate in one-on-one investor meetings at the Benzinga Healthcare Small Cap Conference. The event is scheduled to be held virtually on Sept. 29-30, 2021, with Ramsden’s presentation to begin at 4:00 p.m. ET on Wednesday, Sept. 29. Interested parties should visit https://ibn.fm/Wpkw4 to register for the event. In addition, the company announced it has granted a total of 10,000 stock options to certain employees pursuant to the terms…

Continue Reading

MondaySep 27, 2021 2:37 pm

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Announces Launch of the ‘Desire Project’

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research in psychedelics, today unveiled its “Desire Project,” a clinical research program focused on the treatment of female hypoactive sexual desire disorder with MDMA-assisted psychotherapy. According to the update, the research program will mark the first psychedelic-based treatment program targeted at addressing what is clinically known as Hypoactive Sexual Desire Disorder (“HSDD”), a common sexual disorder characterized by persistent low sexual desire and emotional distress not attributable to an existing medical condition or relationship issue. Current estimates indicate that HSDD affects 10% of…

Continue Reading

MondaySep 27, 2021 12:34 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Enters Strategic Commercial Agreement with UK Licensee

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced its entry into a global commercial contract with MySugarWatch DuoPack Limited (“MSW-DP”). Under the agreement, the continuous glucose monitor (“CGM”) and sensors will be provided as duo packs with prescription only medicines that are widely prescribed for people with type 2 diabetes. MSW-DP has been granted global rights to the sugarBEAT(R) non-invasive CGM devices and sensors, to be provided solely as duo packs with these medicines, under the terms of the agreement, which Nemaura will…

Continue Reading

FridaySep 24, 2021 12:54 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Release FY 2021 Financial Report and Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has released its financial results and corporate update for FY 2021. In addition, the company announced a conference call and webcast, in which company leadership will discuss the report. Interested parties can access a replay of the webcast for 90 days. Corporate highlights of the report include the definitive agreement the company entered to acquire BayMedica Inc., a private company specializing in the manufacture and commercialization of rare cannabinoids; the announcement that INM’s IntegraSyn(TM) cannabinoid manufacturing approach had achieved a level of 2g/L cannabinoid yield,…

Continue Reading